Search academic texts

Information × Registration Number 0214U006742, 0111U001426 , R & D reports Title Mechanisms of chronic myeloid leukemia evolution as a result of interrelation between genetically disturbed substrate cells and certain regulatory mechanisms of the patient body popup.stage_title Head Maslyak Zvenyslava Volodymyrivna, Registration Date 12-02-2014 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 Study subject - 104 patients with chronic myeloid leukemia (CML) , karyotype of bone marrow cells, oncogene BCR-ABL, vascular endothelial growth factor (VEGF), tumor necrosis factor alpha (TNF-a), imatinib (IM), nilotinib (NI). Aim - to investigate clonal evolution in CML, to establish parameters for predicting clinical course and subsequent correction of the treatment strategy in the management of CML with tyrosine kinase inhibitors (TKI) . Methods - clinical, cytological, cytogenetic, molecular-genetic, immunoassay, statistical. Optimal response was achieved only with imatinib as the first-line therapy. Cytogenetic response to IM treatment was 2-3 times worse in patients pretreated with busulfan of hydroxyurea. The lowest survival rates were obtained for patients at high risk according to Sokal and EUTOS. Additional cytogenetic aberrations during IM therapy were found both in Ph-positive and Ph-negative cells. The first were 4 times more frequent in patients with no or lost cytogenetic response (CyR), the other - in complete (CCyR) and partial cytogenetic response (PCyR) . The different frequencies of additional chromosomal aberrations according to the prior treatment were established. The most frequent were gene BCR/ABL amplification, trisomy 8 and isochromosome 17q. Trisomy of chromosomes 19 and 21 were less frequent. Survival of patients differed significantly in the groups with the presence or absence of clonal evolution. Survival was also different in patients achieving CCyR, losing it or having no CyR . Mutations in BCR/ABL gene were identified in 34 % of patients refractory to IM. The survival of these patients did not differ from the patients without mutations. Levels of VEGF and TNF-a prior to TKI exceeded normal, but starting from 1.5 months of treatment, their significant reduction was observed. More informative was level of VEGF. Analysis of survival, depending on its level showed that determination of VEGF dynamically had prognostic significance. On the basis of significant differences in the survival of patients, depending on prior therapy, clonal evolution, cytogenetic response and dynamics of VEGF level at 3, 6 and 12 months of IM treatment these parameters can be used for prognosis if quantitative PCR is not available. The results were introduced into practice of the hematological departments in the regions supervised by institution, 5th municipal hospital in Lviv, consultative polyclinic of SI "IBPTM NAMS". The 22 scientific papers were published, a patent for useful model of Ukraine was received, 1 newsletter was submitted for publication. Product Description popup.authors Бойко Ольга Ігорівна Везденко Лідія Орестівна Виговська Ярослава Іллівна Даниш Ольга Йосипівна Дяків Галина Львівна Кароль Юрій Степанович Котлярчук Костянтин Богданович Лозинський Ростислав Юрійович Лук'янова Анна Сергіївна Лукавецький Лесь Миронович Мазурок Анна Антонівна Мельник Марія Іллярівна Мельник Марія Іллярівна Павлишин Анна Михайлівна Пеленьо Наталія Василівна Примак Софія Василівна Сімонова Мар'яна Іванівна Тераз Софія Степанівна popup.nrat_date 2020-04-02 Close